Chronic Baroreflex Activation Effects on Sympathetic Nerve Traffic, Baroreflex Function, and Cardiac Haemodynamics in Heart Failure: A Proof-of-Concept Study
Open Access
- 28 July 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 16 (9) , 977-983
Abstract
Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device‐based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF. Methods and results In a single‐centre, open‐label evaluation, patients with NYHA class III HF, EF P < 0.01). Concomitant improvements occurred in baroreflex sensitivity, EF, NYHA class, quality of life and 6 min hall walk (6MHW) distance (P ≤ 0.05 each). On an observational basis, hospitalization and emergency department visits for worsening HF were markedly reduced. One complication, perioperative anaemia requiring transfusion, occurred during the study. Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.Keywords
Funding Information
- CVRx, Inc.
This publication has 38 references indexed in Scilit:
- Electromechanical Dyssynchrony and Resynchronization of the Failing HeartCirculation Research, 2013
- Effects of Chronic Baroreceptor Stimulation on the Autonomic Cardiovascular Regulation in Patients With Drug-Resistant Arterial HypertensionHypertension, 2009
- Chronic Baroreceptor Activation Enhances Survival in Dogs With Pacing-Induced Heart FailureHypertension, 2007
- Excessive Sympathetic Activation in Heart Failure With Obesity and Metabolic SyndromeHypertension, 2007
- Sustained Sympathoinhibitory Effects of Cardiac Resynchronization Therapy in Severe Heart FailureHypertension, 2004
- Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure PatientsHypertension, 2003
- Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathyClinical Science, 2001
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984
- Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction.Circulation, 1984
- Vasodilator Therapy for Heart FailureCirculation, 1973